FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:333-334 January 29, 1998 Number 5 Next

Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor for Crohn's Disease

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Targan, S. R.

To the Editor: We question whether the study of monoclonal antibody cA2 to tumor necrosis factor , reported by Targan and colleagues (Oct. 9 issue),¹ specifically establishes the efficacy of the strategy of using antibody to tumor necrosis factor . The cA2 binds complement and has been reported to cause a profound monocytopenia in patients with rheumatoid arthritis,² an action that could itself be therapeutic in patients with Crohn's disease (though potentially hazardous) and that might explain why the results reported by Targan et al. were not dose-dependent. Did monocytopenia occur in the present study? If so, was there any . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.